Serum PGI2 stabilizing factor (PSF) was purified from human serum to a single protein with a molecular weight of 28,000 D by SDS-PAGE. Analyses of NH2-terminal sequence (32 residues), COOH-terminal sequence (3 residues) and the composition of amino acids disclosed its homology with human apolipoprotein A-I (Apo A-I), a major apolipoprotein of HDL.
Introduction
PGI2 (prostacyclin) is synthesized by the vascular endothelium and smooth muscle. PGI2 is a potent vasodilator and inhibitor of platelet aggregation (1) . Two factors in serum are reported to regulate PGI2 metabolism: PGI2 synthesis stimulating factor and PGI2 stabilizing factor (PSF)' (2) . PGI2 is an unstable substance. However, it binds to PSF resulting in a more stable substance. Recently, decreased PSF activity has been reported in thrombotic disorders (acute myocardial infarction (2) , thrombotic thrombocytopenic purpura (3) and ischemic stroke) (4) and PSF is suspected to play an important role in the pathogenesis of the thrombus formation in these diseases. Albumin has been considered as a candidate for the stabilizing factor (5-7). However, PSF has not been analyzed biochemically.
In this study, we purified this factor and found that this factor is identical to Apo A-I, a major apolipoprotein of HDL. We also found that Apo A-I is present in the albumin preparations. Our finding suggests that the antiatherogenic acAddress reprint requests to Dr. Kawai [3H]6-keto-PGF1,a can not bind PSF. Protein was determined by the method of Lowry et al (13) .
Electrophoresis. SDS-PAGE was performed using the 2/16 gradient gel (Pharmacia) for Fig. 2 . For Fig. 5 , Phast-system (Pharmacia) was used with 10-15% gel. Procedures were performed according to the manufacturer's directions. Western blotting was performed using the Bio-Rad system (Bio-Rad Laboratories, Richmond, CA) and the blotting detection kit (Amersham Corp., Arlington Heights, IL). The antibody for human Apo A-I was obtained from Daiichi Chemical Pharmaceutical Company (Tokyo, Japan).
NHrterminal, COOH-terminal and amino acid analysis. Subunits were separated by reversed-phase HPLC (Cosmosil 5TMS-300 column, 4.6 mm X 50 mm, Nakarai Chemical Co., Kyoto, Japan) eluted with a linear gradient from 20% B buffer to 80% B buffer in 30 min at a flow rate of0.8 ml/min at 350C. The column was monitored at 220 nm (buffer A: 10% CH3CN, 90% water, 0.1% trifluoroacetic acid (TFA), buffer B:90% CH3CN, 10% water, 0.1% TFA). For the collected peak, automated Edman degradation was performed on a gas vapor sequencer (model 470 A; Applied Biosystem, Foster City, CA). This instrument is equipped with an on-line isocratic phenylthiohydantoin amino acid analysis system using a Spectra-Physic HPLC and a Senshu-Pak SEQ-4 column (4.6 mm X 30 cm; Senshu Chemical Company, Tokyo, Japan). The COOH-terminal analysis was performed by the digestion of carboxypeptidase Y. The amino acid composition of HPLC-purified protein was obtained after 20 h of hydrolysis (4 N methanosulfonic acid, at 1 10C) followed by analysis on an Irika model A-5500 analyzer (Irika Co., Tokyo, Japan).
Preparation ofHDL, LDL, Apo A, C, D, and E. HDL and LDL were prepared from pooled human serum (10 normal men) by the method of Havel et al. (14) . Apolipoproteins A, C, D, and E were prepared from human (very) low density lipoprotein or HDL by the methods of Edelstein (15) , Shore (16) , and Shelburne (17) , respectively. Cholesterol, phospholipid, and triglyceride were determined with the analyzing system by Wako Pure Chemical Co. (Tokyo, Japan). Nascent HDL. Nascent HDL was reconstituted from Apo A-I (1.2 mg; Sigma Chemical Co., St. Louis, MO), bovine brain sphingomyelin (2.5 mg) and dipalmitoylphosphatidylcholine (2.5 mg, both from Sigma Chemical Co.) (18, 19) .
Determination ofApoA-I levels. Apo A-I level was determined by a single radial immunodiffusion (SRID) method (Daiichi Chemical Pharmaceutical Co.). This antiserum did not bind to albumin.
Evaluation ofPGI2 half-life. The stability of PGI2 was determined by a quantitative HPLC method (5, 20) . Samples were injected onto a YMC A-314 Cl8 column (6 mm x 30 cm; Yamamura Chemical Industry, Kyoto, Japan). The mobile phase was a methanol/boric acid buffer (40 mM, pH 8.9) = 55/45 (vol/vol) with a flow rate of 1.0 ml/min. This method separates and quantitates both PGI2 and 6-keto-PGFI, based on their characteristic absorption of ultraviolet at 204 nm. PGI2 and 6-keto-PGFI. was obtained from ONO Pharmaceutical Co. (Osaka, Japan).
Apo A-I immunoaffinity column. The Apo A-I immunoaffinity column (21) was obtained from Otuka Pharmaceutical Co. (Tokushima, Japan). Serum (0.25 ml) was applied to the column (1 ml of gel volume), which was equilibrated with 0.01 M PBS (pH 7.2). After washing with 20 ml of 0.01 M PBS (pH 7.2), the Apo A-I particles was eluted with 7.5 ml of0.5 M NaCl/l M acetic acid. After the neutralization by 3.5 M Tris. HCl (pH 7.4), the eluent was dialyzed against 0.01 M PBS (pH 7.2).
Results
Human serum (50 ml) was applied to the Blue-Sepharose CL-6B (Pharmacia) column. PSF appeared by the elution of 0.2 M sodium thiocyanate (NaSCN) in 50 mM Tris-HCl, pH 7 .4 ( Fig. 1 A) . Albumin was eluted in the second peak. The recovery rate was 60%. The eluent was concentrated using a PM-10 membrane in a stirred cell (Amicon Corp., Danvers, MA). The concentrate was subjected to gel-permeation chromatography (Sephacryl S-300; Pharmacia) ( Fig. 1 B) . The recovery rate was 73%. The fractions of PSF were pooled and concentrated, and then subjected to high-performance adsorption and gel-filtration chromatography (GS-620P; Asahi Chemical Industry, Tokyo, Japan) (Fig. 1 C) . The activity was present in the last tailing peak. The recovery rate was 62%. SDS-PAGE of that portion showed a single band of 28,000 D (Fig. 2) . The native molecular weight was determined by gelpermeation chromatography with a Diol-300 column (1 cm X 50 cm; Yamamura Chemical Industry). The estimated value was 224 kD. The NH2-terminal amino acid sequence of this protein was H2N-Asp-Glu-Pro-Pro-Gln-Ser-Pro-Trp-Asp-ArgVal-Lys-Asp-Leu-Ala-Thr-Val-Tyr-Val-Asp-Val-Leu-LysAsp-Ser-Gly-Arg-Asp-Tyr-Val-Ser-Gln. This the addition of HDL, the half-life was prolonged from 4.8 min (o) to 22.3 min (.). Albumin has been reported to bind PGI2 and to prolong PGI2 activity (3) (4) (5) (6) (7) . Indeed, the PSF activity was found in human albumin (Cohn fraction V albumin, Sigma). The contaminated band of Apo A-I was detected by SDS-PAGE with silver staining (protein band 7 in Fig. 5 B) . The No. 7 protein in Fig. 5 B was identified as Apo A-I by the same purification method. This protein was also identified as Apo A-I using Western blotting. After the purification of albumin with BlueSepharose CL-6B as described in Fig. 1 A, the purified albumin showed no band ofApo A-I (Fig. 5 A) and was without activity.
There was a linear relationship between Apo A-I concentration in albumin (Cohn fraction V) and albumin concentration (open circles, Fig. 3 B) . PSF activity also varied in parallel with concentration of Apo A-I in albumin (open circles, Fig. 3  A) . Moreover, we were able to eliminate this PSF activity from human serum using an Apo A-I immunoaffinity column. From the above results, PSF in serum was considered to be Apo A-I. 
Discussion
We have succeeded in purifying the prostacyclin stabilizing factor (PSF) in serum and identified this factor as Apo A-I. The purification was done by affinity chromatography by BlueSepharose CL-6B, gel-permeation chromatography by Sephacryl S-300 and high-performance adsorption and gel-filtration chromatography by GS-620 P. By these column chromatographies, this PSF was purified to a single protein by SDS-PAGE. The overall recovery rate was 27%. During the purification, we examined the PSF activity at protein concentration of 1 g/dl. At 1 g/dl albumin concentration in 50 mM Tris. HCI buffer, pH has shifted from 7.4 to 7.2. Albumin is a rather acidic protein and a 50-mM buffer might not be sufficient to buffer the acidification by albumin itself. In 100 mM Tris * HC buffer pH 7.4, pH did not change.
Thus, we carefully tested the activity of this fraction in 100 mM Trise HCl buffer instead of 50 mM. However, PSF activity was not also found in albumin fraction.
NH2-terminal analysis of this 28-kD protein revealed its identity with that of Apo A-I (22). Data on COOH-terminal analysis, and the analysis of amino acid composition were also compatible with those of Apo A-I (22). Apolipoprotein A-II, another apolipoprotein of HDL was not found in the SDS-PAGE shown in Fig. 2 . This protein was separated from Apo A-I with Sephacryl S-300.
The chemical composition of HDL is as follows (24): cholesterol 20%, phospholipid 23%, triglyceride 5%, protein 50%6, and others 2%. By the purification method which we employed (Blue-Sepharose CL-6B, gel-permeation chromatography by Sephacryl S-300 and GS-620P), PSF was purified from serum to Apo A-I, and other apolipoproteins in HDL, such as A-II, C-I, II, and III, D and E were excluded. During this purification, cholesterol content was decreased to 1% and phospholipid content was increased to 42%. Nascent HDL reconstituted by Apo A-I and the phospholipid revealed PSF activity. However, delipidated Apo A-I has no binding activity. Thus, the alpha-helix structure of Apo Aseems to be necessary for this activity. There was a linear relationship between HDL concentration and PSF activity. By delipidation of HDL, the activity of PSF was also lost.
By adding HDL, the half-life of PGI2 prolonged significantly from 4.8 min (at 240C, pH 7.4) to 22.3 min. The mechanism of this prolongation is unknown at this moment. VLDL and LDL have only trace amounts of Apo A-I. These lipoproteins had no effect on the prolongation of the PGI2 half-life.
PGI2 stabilization by albumin has been studied using commercially available albumins (3-7). However, in their papers, the purity of albumin was not examined by SDS-PAGE. As shown in Fig. 5 B, commercially. available albumin (Cohn fraction V) has many contaminated bands. The Apo A-I band is also seen in the gel. This protein was identified as Apo A-I by Western blotting. In other types of albumin, such as fatty acid free or globulin-free albumin, many bands were also seen (data not shown). Purified albumin (Fig. 5 A) has no binding activity. Moreover, it is demonstrated that the comparative study in Fig. 3 A and B shows that Apo A-I in albumin contributes to the binding of PGI2.
HIDL levels were reported to be inversely related to the incidence and mortality rate of coronary heart disease (8-1 1). HDL is considered to promote the removal of free cholesterol from peripheral tissue and its transport to the liver for eventual clearance (25). Apo A-I appears to be a more useful index than HDL cholesterol for identifying patients with coronary artery disease (26) . In addition to the activation of lecithin-cholesterol acyl-transferase (LCAT) (27) , PGI2 stabilization is thought to be an important new function of Apo A-I.
PGI2 is reported to increase cholesteryi ester hydrolysis activity in rabbit aortic smooth muscle cells (28) . At high levels of HDL, this hydrolysis activity may increase through PGI2
stabilization. The increased cholesterol will bind to the high levels of HDL and will be carried to the liver.
Our findings suggest that when HDL and Apo A-I are reduced, the availability of PGI2 at the sites of vascular damage may be reduced, thus inactivating the protection mechanism against platelet thrombus formation and vasoconstriction. 
